Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
SEC Accession No. 0001628280-26-045742
Filing Date
2026-06-26
Accepted
2026-06-26 16:05:29
Documents
20
Effectiveness Date
2026-06-26

Document Format Files

Seq Description Document Type Size
1 S-3ASR spyre-formsx3asrjune2026.htm S-3ASR 404322
2 exfilingfees-s3asr.htm   iXBRL EX-FILING FEES 43414
3 EX-1.2 exhibit12-sx3asr.htm EX-1.2 285585
4 EX-4.2 exhibit42-sx3asr.htm EX-4.2 440580
5 EX-5.1 exhibit51-sx3asr.htm EX-5.1 22867
6 EX-5.2 exhibit52-sx3asr.htm EX-5.2 10209
7 EX-23.1 exhibit231-sx3asr.htm EX-23.1 1860
8 EX-23.2 exhibit232-sx3asr.htm EX-23.2 1965
9 prospectuscover1aa.jpg GRAPHIC 20919
10 ropesgray.jpg GRAPHIC 2242
11 ropesgraya.jpg GRAPHIC 2242
  Complete submission text file 0001628280-26-045742.txt   1405491

Data Files

Seq Description Document Type Size
23 EXTRACTED XBRL INSTANCE DOCUMENT exfilingfees-s3asr_htm.xml XML 13554
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3ASR | Act: 33 | File No.: 333-297063 | Film No.: 261129020
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)